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Abstract
Background: Heat Shock Proteins (HSPs), a family of genes with key roles in proteostasis, have been extensively
associated with cancer behaviour. However, the HSP family is quite large and many of its members have not been
investigated in breast cancer (BRCA), particularly in relation with the current molecular BRCA classification. In this
work, we performed a comprehensive transcriptomic study of the HSP gene family in BRCA patients from both The
Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC)
cohorts discriminating the BRCA intrinsic molecular subtypes.
Methods: We examined gene expression levels of 1097 BRCA tissue samples retrieved from TCGA and 1981 samples
of METABRIC, focusing mainly on the HSP family (95 genes). Data were stratified according to the PAM50 gene
expression (Luminal A, Luminal B, HER2, Basal, and Normal-like). Transcriptomic analyses include several statistical
approaches: differential gene expression, hierarchical clustering and survival analysis.
Results: Of the 20,531 analysed genes we found that in BRCA almost 30% presented deregulated expression (19%
upregulated and 10% downregulated), while of the HSP family 25% appeared deregulated (14% upregulated
and 11% downregulated) (|fold change| > 2 comparing BRCA with normal breast tissues). The study revealed
the existence of shared HSP genes deregulated in all subtypes of BRCA while other HSPs were deregulated in
specific subtypes. Many members of the Chaperonin subfamily were found upregulated while three members
(BBS10, BBS12 and CCTB6) were found downregulated. HSPC subfamily had moderate increments of transcripts levels.
Various genes of the HSP70 subfamily were upregulated; meanwhile, HSPA12A and HSPA12B appeared strongly
downregulated. The strongest downregulation was observed in several HSPB members except for HSPB1. DNAJ members
showed heterogeneous expression pattern. We found that 23 HSP genes correlated with overall survival and three
HSP-based transcriptional profiles with impact on disease outcome were recognized.
Conclusions: We identified shared and specific HSP genes deregulated in BRCA subtypes. This study allowed
the recognition of HSP genes not previously associated with BRCA and/or any cancer type, and the identification of
three clinically relevant clusters based on HSPs expression patterns with influence on overall survival.
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Background
In worldwide terms, breast cancer (BRCA) has the sec-
ond annual incidence (1,670,000 cases) and the fifth
mortality rate (522,000 deaths associated) of overall can-
cers [1]. Classifications of BRCA have been performed
according to clinical features, histological characteristics,
and presence of steroid and/or growth factor receptors.
PAM50 gene expression assay allows the molecular clas-
sification of BRCA based on the expression levels of fifty
genes and sorts BRCA into five intrinsic subtypes:
Luminal A, Luminal B, HER2-enriched (HER2), Basal-like
(Basal) and Normal-like (Normal). This classification
highly correlates with BRCA biological behaviour and has
clinical use due to its prognostic significance [2, 3]. Heat
Shock Proteins (HSPs) are ubiquitous in living organisms
and their expression is rapidly regulated by stress. Histor-
ically they were recognized as proteins induced by heat, al-
though it is now known that various types of physiological
and/or pathological stresses regulate their expression [4].
HSP systems are involved in protein quality control [5],
degradation pathways (ubiquitin-proteasome system,
endoplasmic reticulum associated degradation, autoph-
agy), and regulation of apoptosis [5, 6]. The HSPs belong
to a family of evolutionarily conserved genes that includes
95 genes divided into five subfamilies: 1) type I chapero-
nins (HSP10 and HSP60), BBs chaperonins, and type II
chaperonins (CCT genes) which are grouped under the
Chaperonin subfamily (CHAP); 2) HSP70 (HSPA) and
large HSP 100–110 kDa (which are all included in the
HSP70 family); 3) small HSP 12–43 kDa (HSPB); 4)
HSP90 (HSPC); and 5) HSP40 (DNAJ) [7]. The HSPs re-
lated systems can be disturbed during oncogenesis allow-
ing malignant transformation and/or facilitating rapid
somatic evolution; they have been studied in a wide variety
of cancers, presenting different pro-tumour (stimulating
tumour growth and metastasis) or anti-tumour ac-
tions [4, 8]. Currently, HSPs are emerging as molecular
targets in cancer therapy through the interference of their
diversity of functions in cancer cells by different ap-
proaches. In fact, there are clinical trials for various can-
cers, including BRCA, using HSP-inhibitor compounds
and other HSP-based strategies [9–11]. The information
gathered from diverse studies regarding the role of the
HSPs in different situations associated with cancer fre-
quently provides contradictory overviews. HSP genes (and
encoded proteins) corresponding to HSPA1A/B, HSPB1,
DNAJB1 and HSP90AA1 are the most studied; these have
been tested in various models (cell culture, biopsies, etc.),
nevertheless in the context of BRCA many others HSPs
have not been studied yet. Currently, we have not found
specific studies of the complete HSP gene family in BRCA
integrating the multi-omics platforms available. The par-
ticipation and implications of HSPs involved in different
pathways controlling cell growth, differentiation and
apoptosis emphasize the importance for a thorough and
comprehensive study of all members of these genes. The
purpose of this study is the analysis and integration of
clinical and transcriptomic (RNAseq) data of BRCA
tumour samples from TCGA and METABRIC databases
with emphasis on HSP genes in the five BRCA mo-
lecular subtypes. We hypothesize that the results of
this investigation will generate relevant knowledge of
the HSPs expression landscape, useful in the genomic
and clinical characterization of BRCA.
Methods
Data analyses
Two independent datasets were used in this study: 1)
The “TCGA assembler” v.1.0.3 [12] package was used to
programmatically download, from the publicly available
TCGA (http://cancergenome.nih.gov/) dataset of mam-
mary adenocarcinoma, level 3 standardized (normalized)
and non-standardized (raw counts) mRNA gene expres-
sion levels from 1097 tumour samples and 114 normal
tissue samples measured using the RNA-Seq technology
(RNASeqV2) (May 1, 2015). Available clinical informa-
tion corresponding to 1085 patients was obtained using
the same package and updated with the latest follow-up
available. Samples were obtained from patients with ini-
tial diagnosis of invasive breast adenocarcinoma under-
going surgical resection and that had no prior treatment
for their diseases. Samples were collected between 1988
and 2013, disregarding gender, race, histological type,
disease stage or other co-morbidities (Additional file 1:
Table S1). The tumour sections analysed were required to
contain an average of 60% tumour cell nuclei with less
than 20% necrosis under TCGA protocol standards. The
treatments of patients varied according to the standard of
treatment at time of diagnosis and with the inclusion of
patients under clinical trial protocols. For further informa-
tion about biospecimen collection, processing, quality
control and biomarker assessment, please refer to [3] or to
TCGA website (http://cancergenome.nih.gov). 2) To valid-
ate the HSP clusters detected in the TCGA dataset, the
clinical information and the normalized gene expression
levels of 1981 tumours from patients with breast cancer
were acquired from the METABRIC cohort. [13]. The
METABRIC database analyses 49,576 transcripts with Illu-
mina HT 12 microarray technology and reports patient
overall survival and disease-specific survival. These data
were accessed through Synapse (synapse.sagebase.org, ID:
syn1757063, syn1757053 and syn1757055).
The analysis workflow is summarized in Additional file 2.
All analyses and graphs were performed using R software
environment unless otherwise specified. This study has
been approved by the Bioethical Committee of the
Medical School of the National University of Cuyo,
Mendoza, Argentina (0029963/2015).
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Intrinsic subtype classification
The expression levels of the PAM50 panel genes from
each of the 1097 samples from TCGA were used to carry
out the intrinsic subtype classification of tumours [2]
which was performed using the “Bioclassifier” package,
kindly given by Dr. K. Hoadley of the University of
North Carolina Chapel Hill and available online. To per-
form this task, the normalized expression profile (nor-
malized RNA_SeqV2 RSEM) of the 50 specific genes
was used. Many of these genes are strongly related to
BRCA behaviour and include ESR1, ERBB2, PGR, and
MKI67 among others. To normalize the expression
values from each gene the log2 expression levels were
obtained and subsequently the median expression value
of a subset of samples (50% oestrogen receptor positive
and 50% oestrogen receptor negative population defined
by immunohistochemistry) was subtracted. Once the
samples were classified, principal component analysis,
class to centroid correlation, and hierarchical cluster
evaluations were performed to assess the quality and val-
idity of the classification (Additional files 3 and 4). We
found 89 and 100% concordances with previously re-
ported classifications by Koboldt [3] and Ciriello [14]
respectively (Additional file 1: Table S5). From the
total samples analysed from the TCGA cohort, we found
few cases of the Normal-like subtype (only 3.6%), 51.5%
were Luminal A, 20% were Luminal B, 17% were Basal,
and 7.5% were HER2, which are in agreement with other
studies [15, 16]. All 1981 METABRIC patients were classi-
fied according to the PAM50 classification as described
above and Normal-like patients were excluded from fur-
ther consideration.
Differential gene expression of TCGA samples
To evaluate differentially expressed genes (DEG) two dif-
ferent statistical packages, DESeq2 [17] and EdgeR [18],
were chosen due to their demonstrated good perform-
ance [19]. In this study, we used raw count expression of
20,531 genes from 1211 tissue samples. We grouped
samples according to the subtypes assigned, and then
each group was compared against normal tissue expres-
sion profiles using the standard workflow as presented
in: https://www.bioconductor.org/packages/3.3/bioc/vi-
gnettes/DESeq2/inst/doc/DESeq2.pdf and https://bio-
conductor.org/packages/release/bioc/vignettes/edgeR/
inst/doc/edgeRUsersGuide.pdf. In both cases log2 fold
change values were obtained associated with P values
and False Discovery Rate values (FDR, a modified P
value to correct the eventually false positives) by Benja-
mini and Hochberg method [20]. Results from DESeq2
and EdgeR are summarized in Additional file 5. The
consistency between both methods was compared by
Pearson’s correlation coefficient (mean correlation be-
tween methods 0.948 ± 0.01 SD) and Bland Altman
analysis [21] (mean difference between methods of 0.02
and 97.37% of the measurements within the 95% confi-
dence interval), which evidence high agreement between
both techniques (Additional file 6). We detected a dis-
agreement between both methods in at least one BRCA
subtype in six genes (CRYAA, DNAJB13, DNAJC5G,
HSPA6, HSPB3 and ODF1), all of which presented low
expression levels. EdgeR runs with least computational re-
sources than DESeq2, this motivated its preferential use.
EdgeR ANOVA-like test was used to analyse differential
gene expression within PAM50 subtypes and
HSP-Clusters (Additional file 7).
Heatmap construction and cluster analysis
The values of logarithm base 2 of normalized RSEM
(RNAseq) plus 1 from 1033 patients (males, Normal-like
tumours, and patients without clinical data were ex-
cluded) from the TCGA cohort were used to construct
the HSPs expression matrix. The rows and columns
were sorted based on a hierarchical cluster with average
linkage and Pearson’s correlation distance. According to
Silhouette dendrograms analysis (Additional file 8) pa-
tients were grouped into three clusters: HSP-Clust I,
HSP-Clust II and HSP-Clust III.
Survival model
The survivals analysis was performed according to
REMARK guidelines [22]. The effect of each HSP on
survival was estimated using a univariate Cox propor-
tional hazard model with the survival information of the
1033 patients of the TCGA cohort considered in the
heatmap graphic and cluster analysis. To correct for
multiple testing FDR testing was conducted by
Benjamini and Hochberg method. Once each patient of
the TCGA and the METABRIC training and test set
were classified into one of the three HSP clusters,
Kaplan-Meier curves for each group were generated and
the survival distribution was compared using Log-Rank
test. A multivariate Cox proportional hazard model was
used to determine statistically significant survival differ-
ence between clusters of TCGA cohort. The model was
adjusted to several known prognostic predictors (inclu-
sion criteria): lymph node status, tumour size, age,
tumour stage, and PAM50 subtypes. As exclusion cri-
teria we considered: males, patients with unknown meta-
static status at the time of diagnosis, and Normal-like
subtypes. From this filtering 1003 patients were left, with
81 events registered. The sample size was not considered
a priori and all available patient data within inclusion
criteria were considered.
Nearest centroid classifier
To train a HSP single-sample-predictor with the METABRIC
dataset, samples gene expression levels were scaled
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and only probes that were associated with the 95
HSPs where used in the classifier. In cases where
there was more than one probe matching a single
gene, all probes values were averaged and collapse
into one. From the 95 HSP genes, HSPA7 did not
match to any of the probes analysed and those HSP
genes that presented low expression levels in the
TCGA cohort (DNAJB8, DNAJC5G, DNAJB3, ODF1,
CRYAA and HSPB3) were not considered to train the
classifier. The dataset was randomly divided into a
training set (n = 915) and a test set (n = 914), then a
hierarchical clustering algorithm with average linkage
and Pearson’s correlation distance was applied to the
training dataset and the resulting dendrogram tree
was cut to divide the set of patients into three differ-
ent HSPs expression profile groups. From each clus-
ter, the corresponding centroid vector was calculated
and the samples in the test set were labelled accord-
ing to the class centroid from which each sample pre-
sented highest Spearman correlation.
Results
Transcriptomic analysis evaluating the RNA expression
profile in TCGA BRCA cohort
We first evaluated the absolute normalized expression
levels of the 95 HSP genes. The overall trend indicates
that HSPs were highly expressed in tumour samples
(one-sided Mann-Whitney U test P val = 1.256e− 10),
nevertheless, a more detailed study showed a group of
six genes (DNAJB8, DNAJC5G, DNAJB3, ODF1,
CRYAA, and HSPB3) with very low expression levels in
almost all the samples and was not detected in at least
50% of the cohort or more. On the other hand, six HSPs
(HSP90AB1, HSP90AA1, HSPA8, HSP90B1, HSPA5, and
HSPA1A) were ranked in the top 100 most expressed
mRNAs of BRCA (hypergeometric test P val = 4.09− 07).
(Fig. 1 and Additional file 1: Table S2). The rest of the
HSPs were distributed in a wide range of expression. Al-
most all members of the Chaperonin subfamily (TCP1,
CCT2, CCT3, CCT4, CCT5, CCT6A, CCT7, and CCT8)
were also expressed at similarly high levels. It is import-
ant to note that the HSPB subfamily, except HSPB1, ap-
peared with low transcript expression levels.
We continued the analysis evaluating DEG comparing
BRCA tissues against normal tissues. In this study we
considered only genes that showed absolute values of
log2 fold change (log2FC) > 1 and statistical significance
(FDR < 0.05). The tabulated results (Additional file 5)
show that in BRCA there were 3994 upregulated and
2155 downregulated genes. To our knowledge, this is
the first report of the DEG between tumours and normal
tissues taking into account PAM50 groups of RNAseq
BRCA data (1097 patients). With respect to HSP
genes, 13 were upregulated and 11 were downregulated
(Additional file 1: Table S3). Deregulation of HSP genes
increased in BRCA subtypes as follows: Luminal A,
Luminal B, HER2 and Basal. To achieve a better statistical
interpretation volcano plots were used (Fig. 2). These
graphs allow the contextualization of the HSP genes re-
spect to the rest of the genes letting a complete appreci-
ation of gene expression changes that were modulated
differentially in the entire cohort (Fig. 2 tumour total) and
between the intrinsic BRCA subtypes (Fig. 2). The patients
were subdivided according to the PAM50 classification to
investigate whether the intrinsic subtypes of BRCA mani-
fested different expression of HSP genes. The PAM50
classification is a “single sample predictor” and classifies
each of the samples in 5 tumour intrinsic subtypes [2].
From a total of 1097 samples 566 were classified as
Luminal A, 217 as Luminal B, 82 as HER2-enriched,
192 corresponded to Basal and 40 were Normal-like
(Additional file 1: Table S4). The comparison of the
correlative immunohistochemical characteristics of each
tumour was included; these results appeared congruent
with the molecular classification (Additional file 1:
Table S4). In the case of upregulated HSP genes, the log2
fold-change mean and standard deviations (SD) in the dif-
ferent subtypes ranged between 1.38 and 1.64 and 0.31 to
0.69 respectively; the downregulated genes showed log2
fold-change mean in the range of 2.34 to 3.62 and were
more dispersed (SD = 1.36 to 2.26) compared to upregu-
lated genes. Surprisingly we found that several HSPs were
within the first hundred genes with the lowest FDR values
in Luminal A and Luminal B, which points out that some
HSPs DEG in BRCA shows remarkable steady differences
between normal and tumour samples.
After exploring HSPs expression changes, we found
many deregulated HSP genes, some of which were spe-
cific for certain molecular subtypes while others were
shared by different intrinsic subtypes (Fig. 3). In particu-
lar, this analysis revealed that 38 of the 95 HSP genes
were found differentially expressed. In the case of
downregulated genes, a group (DNAJB4, DNAJC18,
HSPA12A, HSPA12B, HSPB2, HSPB6 and HSPB7) pre-
sented decreased transcript levels in all BRCA molecular
subtypes while some HSPs showed subtype specific
downregulation (DNAJC27 and DNAJC12 in Basal and
BBS12 and DNAJC5G in HER2). Others HSPs presented
decreased levels of transcripts shared between different
subtypes (HSPB8 between HER2 and Basal and CRYAB
and SACS between HER2, Luminal A and Luminal B tu-
mours). Evaluating the upregulated genes, we found a
more complex combination where only DNAJC5B was
upregulated in all subtypes. HSPB1, DNAJB13, DNAJC1
and DNAJC22 were upregulated in all except in the
Basal subtype. The Basal subtype showed the highest
number of specific upregulated genes (DNAJC2,
DNAJC6, HSPA5, HSPA14 and CRYAA), DNAJA3 and
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CCT2 were upregulated in Luminal B, and DNAJB3 was
only upregulated in HER2 tumours. Luminal A did not
have any specific upregulated HSP.
Fold change expression values of the different HSP
subfamily
We next proceeded to compare the magnitude the HSPs
DEG pattern in the BRCA tissues arranging the HSPs in
their five subfamilies. Figure 4 shows that the CHAP
subfamily (14 members) appeared upregulated in BRCA
with only three members (BBS10, BBS12 and in a lesser
degree CCT6B) downregulated. In this figure we can
also see that most of the HSP70 subfamily members
were upregulated while only two members (HSPA12A
and HSPA12B) were strongly downregulated. HSPA4L
showed a particular profile, its expression decreased in
HER2 and Luminal A cancers only. The study of the
HSPB subfamily showed interesting characteristics.
Incremented transcripts levels of HSPB1, HSPB9 and
HSPB11 were observed in most BRCA subtypes, CRYAA
was upregulated only in Basal subtype and ODF1
showed an increased expression in Luminal A tumours
that was not significant by the Deseq2 method. Interest-
ingly, the genes CRYAB, HSPB2, HSPB6 and HSPB7
were strongly downregulated in all BRCA subtypes. The
HSPC subfamily involves HSP90 genes with well-known
clinical implications in cancer [23]. HSPC members
showed mild positive fold changes in all BRCA subtypes.
It is of interest to mention that several HSP genes have
relatively high expression levels in normal tissues,
therefore in these cases fold changes in expression
levels between normal and cancer tissues are less pro-
nounced but could be of important biological signifi-
cance. (e.g. HSP90AA1 have a fold change of 0.98).
The large DNAJ subfamily revealed a mixed behav-
iour, some members (DNAJA2, DNAJB1, DNAJB8,
DNAJB9, DNAJC8, DNAJC25) showed null variations,
others were upregulated (DNAJA1, DNAJA3, DNAJA4,
DNAJB2, DNAJB11, DNAJC1, DNAJC2, DNAJC5,
DNAJC5B, DNAJC9, DNAJC10 and GAK) and some were
a b
Fig. 1 HSPs expression in breast cancer. a) The mean expression of each gene in all cancer samples was calculated and sorted in decreasing order.
HSP genes were localized with a red x. Note that six HSP genes are above the orange line of the top 100 expressed genes. b) The graphs show the
RNA expression distribution of HSP genes in the cohort. Note that figure is thicker were the values are more frequent
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downregulated (DNAJB4, DNAJC18, DNAJC27, DNAJC28
and SACS) in all subtypes. Several interesting expression
profiles of DNAJ members need to be especially mentioned.
For example, DNAJC12 appeared strongly upregulated in
Luminal A and B, in contrast to the Basal subtype where
this gene appeared downregulated. DNAJB3 transcripts ap-
peared strongly upregulated in the HER2 BRCA subtype
and DNAJC22 appeared upregulated in Luminal A,
Luminal B and HER2 subtypes. A summary of the HSP
subfamilies fold change trends across PAM50 classes is
depicted in Additional file 9 to grasp a better understanding
of the HSP groups changes and variability in the different
subtypes which reveals that a complex regulation is
active on every HSP subfamily, even for members of
the same group.
Beyond particular cases, less marked but important
differences were found in the overall expression patterns
of HSP gene families between subtypes. Primarily, HSPH
(from the HSP70 superfamily), HSP90 (HSPC), and type
I and type II chaperonins (from the CHAP family) were
found expressed at higher levels in Luminal B, HER2
and Basal tumours than in Luminal A subtypes, while
for the HSPB family, Basal tumours showed an overall
less marked decrease of these group of genes with
Fig. 2 Differential expression of total genes in breast cancer. Volcano plots of genes expression analysis accomplished by Edge R method. In the
x-axis the log2 fold change respect to normal tissue is represented, while in y-axis the -log10 of FDR is shown (the higher values show smaller FDR).
Observe that HSP genes with log2 fold change > 1 and FDR < 0.05 are indicated as red circles. The green symbols at the top of the subpanels indicate
genes with very small FDR (FDR < 5e− 324). Significant fold changes of non-HSP genes are light blue coloured
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respect to normal tissue, which represents greater ex-
pression of them with respect to the rest of the subtypes,
especially in relation to HER2 and Luminal B types
(Additional file 10 A).
HSPs expression variability and clinical outcome
To investigate whether the complex regulation of HSP
genes was associated with clinical outcome, we per-
formed an integrated transcriptomic analysis of the 95
HSP genes in the TCGA BRCA patients with known
follow-up (n = 1033; Normal-like subtypes excluded). It
is well-known that several HSPs have clinical correlates,
the best example is probably HSP90AA1 that it is used
as an adverse prognostic factor not only in BRCA but
also in other cancers [23]. In order to get further infor-
mation of the clinical relevance of HSPs, we performed
an overall survival analysis by Cox univariate model
based on the expression levels of each HSP. We
observed 23 HSP genes with clinical statistical signifi-
cance from which five genes were associated with a good
prognosis (HSPA2, DNAJB5, HSCB, HSPA12B and
DNAJC4) and 18 (CCT6A, DNAJA2, HSPA14, CCT7,
HSPD1, CCT2, HSPA4, DNAJC6, CCT5, SEC63, HSPH1,
CCT8, CCT4, HSP90AA1, HSPA8, DNAJC13, HSPA9
and TCP1) with a poor prognosis (Table 1).
Next, we explored whether the BRCA patients could be
grouped into clinically relevant clusters based on HSPs ex-
pression patterns. To test this hypothesis we performed
an unsupervised hierarchical cluster analysis that sepa-
rated the TCGA cohort into three main branches (Fig. 5).
The three groups were called HSP-Clust I (red in Fig. 5),
HSP-Clust II (green) and HSP-Clust III (orange). These
three HSP clusters corresponded to PAM50 classification
as follows: the HSP-Clust I had 83% of Luminal A tu-
mours, HSP-Clust II was composed mainly by Basal-like
tumours (92%), and the HSP-Clust III was the most het-
erogeneous group with 44% of Luminal A tumours and
40% of Luminal B tumours (Fig. 6a). The HER2 subtype
was dispersed into the three HSP groups, but the majority
were seen in the HSP-Clust III. The Kaplan-Meier curves
of the HSP clusters showed highly significant differences
in overall survival between groups (Fig. 6b, P = 0.0022),
letting us identify a low-risk group (HSP-Clust I) and a
high-risk group (HSP-Clust III). Multivariable analyses of
HSP-Clust I against HSP-Clust II and HSP-Clust III ad-
justed for known clinical covariates (tumour size, node
status, age, and tumour stage) showed different survival
rates for the HSP-Clust II, with a hazard ratio = 2.829 (CI
95% = 1.55–5.17) and P value = 0.0007; and HSP-Clust III
hazard ratio = 2.003 (CI 95% = 1.18–3.39) and P value =
0.01 (Fig. 7a). We also tested a model including the intrin-
sic molecular subtypes.In this case the P values of
HSP-Clust coefficients became non-significant (Fig. 7b),
which suggests that HSP-Clusts effect on survival is re-
lated to PAM50 subtypes. In order to validate the
HSP-Clusts found, we used the METABRIC cohort di-
vided in a training and test set to reproduce our results.
Briefly, by a hierarchical cluster algorithm we divided the
training set into three distinct groups which were consist-
ent with the HSP-Clusts found in the TCGA dataset
(Additional file 11 A) (TCGA HSP-Clust I vs. METABRIC
HSP-Clust I with a correlation factor = 0.87, TCGA
HSP-Clust II vs. METABRIC HSP-Clust II with a correl-
ation factor = 0.82 and TCGA HSP-Clust III vs. METAB-
RIC HSP-Clust III with a correlation factor = 0.7).
Centroids for each HSP-Clusts from the training set were
used to classify samples from the test set. The centroids
obtained from the test sets were in agreement with the
others centroids (Additional file 11 A). The PAM50 sub-
type distribution regarding HSP-Clusts was similar in both
sets (Additional file 11 B). The overall survival of the
HSP-Clusts corresponding to training and test sets showed
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Fig. 3 Venn diagrams showing overlapped and specific differentially
expressed HSPs in intrinsic subtypes of breast cancer. The figure
shows a summary of HSP genes expression analysis performed by
Edge R method (fold-change > 2, FDR-adjusted P values < 0.05,
and with no disagreement mean between the EdgeR and
DESeq2 methods). Normal group was discarded based on the
low number of cases. a Down-regulated HSP genes. b Up-
regulated HSP genes
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a significant difference between HSP groups (both training
and test set had a Log-Rank test with a P value < 0.0001)
(Additional file 11 C).
It is interesting to note that there is a significant (but
not complete) overlap between BRCA PAM50 intrinsic
subtypes and HSP-Clusts. For instance, HSP-Clust I is
enriched with Luminal A tumours and also presents
lower expression levels of HSPH, HSPC and type I and
II chaperonins compared to HSP-Clust II and HSP-Clust
III, which are enriched with Basal and Luminal B tu-
mours respectively. HSP-Clust II presents significantly
higher levels of some HSPB genes such as HSPB2,
HSPB3, CRYAA and CRYAB compared to the others
HSP subtypes (a pattern that was also observed in
Basal-like tumours). HSP-Clust III is enriched with
DNAJA gene expression (similar to the Luminal B and
HER2 subtypes) (Additional file 10 B).
Discussion
This is the first comprehensive study examining the
whole HSP family in breast cancer patients. The HSP
family, characterized by 95 genes and one pseudogene,
represents only 0.46% of the 20,531 analysed genes. In
this study, we found that in BRCA almost 30% of the
Fig. 4 Diagram showing a summary of HSPs expression grouped in subfamilies in breast cancer according to the intrinsic molecular subtypes.
In the figure, the diameter of the circles shows the log2 fold change assessed by EdgeR method. The circles in green show downregulated genes
and the red ones represent upregulated genes. The circle opacity is related to the FDR values, circles with FDR > 0.05 are transparent and therefore
not depicted. The figure makes emphasis on fold change expression values regardless any threshold
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total genes were deregulated (19.45% upregulated and
10.5% downregulated), where the HSP family accounts
for 0.39% of this deregulation (0.32% of the upregulated
genes and 0.52% of the downregulated). Several reasons
have been mentioned to explain HSP misregulation in
cancer: by the stressful situations found in cancer tissues
[4], to increase the stabilization of transcription factors,
receptors, protein kinases and other proteins that lie
along the pathways of normal to cancer transition [24],
and by the oncogenic agents/events that directly affect
the heat shock response [25]. The activation of Heat
Shock factors (HSF) during cancer progression can in
turn explain the activation of the HSPs molecular chap-
erones [26, 27]. Therefore, considering that cancer tis-
sues are subjected to several stressful situations we
expected to see more upregulated HSPs (n = 13) and
fewer downregulated (n = 11). At this point we have to
say that the expression levels of several HSPs were very
close to the cut-point used (log2 fold-change = ±1), this
happened for example with the HSPC family which
codes for the HSP90 (all appeared with a certain level of
upregulation, see Fig. 3). In any case, it is evident that in
BRCA the expression levels of several HSP family mem-
bers are affected. Upregulation was noted mainly in the
CHAP and HSPC family members while the greatest
downregulation was observed in most HSPB members
(Fig. 3 and Additional file 9). The downregulation of the
small HSPs agrees with a recent report [28]. The HSP70
superfamily (which includes the HSP70 and HSP110 or
HSPH family) and the DNAJ members showed variable
results with ups and downs.
The present study revealed that deregulation of the
HSPs varied according to the BRCA molecular subtype.
Of importance at this point is: what are the functional
implications of the up- and down-regulation of the HSP
genes in each breast cancer subtypes? This is not an easy
point to address because in the present report we are
finding alterations in HSP genes that are little known to
be linked with breast cancer; moreover others like
DNAJB3 (increased in HER2 subtype), DNAJB13 and
DNAJC22 (increased in Luminal and Basal subtypes),
and SACS (increased in all subtypes) have not been
related with any cancer type. Let’s begin with the
Chaperonin family. The members of this group can be di-
vided into three distinct subgroups: Type I chaperonins,
established by HSPE1 and HSPD1 genes (also known by
their bacterial names GroES and GroEL or HSP10 and
HSP60 respectively), type II chaperonins forming the
T-complex protein-1 ring complex (TRiC) which is
formed by a double ring structure with eight distinct
subunits (TCP1 and CCT genes) working as an ATP
dependent protein folding machinery [29], and finally the
BBS group of genes (BBS10, BBS12 and MKKS) that in
conjunction with the TRiC complex mediate the BBSome
assembly [30]. Of this group of genes, HSPD1, HSPE1,
CCT3 and CCT5 were overexpressed in Basal, HER2 and
Luminal B subtypes (more aggressive BRCA tumours).
HSPD1 and HSPE1 are located on chromosome 2
arranged in a head-to-head orientation and both are im-
plicated in macromolecular protein assembly and mito-
chondrial protein import, while CCT3 and CCT5 form a
protein complex folding various proteins including actin
and tubulin upon ATP hydrolysis and, as part of the BBS/
CCT complex, they are involved in the assembly of the
BBSome, which in turn is implicated in ciliogenesis regu-
lating transports vesicles to the cilia [30]. At this point we
have to remember that breast cancer cells, mainly stem
cells, have primary cilia (a non-motile microtubule based
cell-surface organelle) that acts as a cellular antenna for
receiving signaling pathways involved in the regulation of
cell proliferation, differentiation and migration [31, 32].
Therefore our study adds evidence to an important role of
CCT3 and CCT5 in the more aggressive BRCA tumours:
Basal, HER2 and Luminal B subtypes. CCT3 has been in-
volved in mitosis progression and associated with poor
Table 1 Univariate Cox proportional hazard risk of breast cancer
based on HSP expression. Regression coefficients, hazard risk
coefficients, standard error, P value and FDR are presented.
Only HSP genes with FDR < 0.05 are shown
Gene Coefficient HR Coeff SE P-val FDR
HSPA2 −0.35 0.71 0.10 < 0.001 0.005
DNAJB5 −0.32 0.73 0.10 0.002 0.011
HSCB −0.29 0.75 0.11 0.009 0.037
HSPA12B −0.29 0.75 0.10 0.003 0.016
DNAJC4 −0.27 0.76 0.10 0.006 0.027
CCT6A 0.22 1.25 0.08 0.009 0.037
DNAJA2 0.25 1.29 0.08 0.002 0.011
HSPA14 0.27 1.32 0.09 0.001 0.009
CCT7 0.28 1.32 0.11 0.008 0.034
HSPD1 0.30 1.35 0.10 0.003 0.013
CCT2 0.30 1.35 0.08 < 0.001 0.001
HSPA4 0.31 1.36 0.11 0.005 0.025
DNAJC6 0.34 1.40 0.11 0.002 0.011
CCT5 0.35 1.42 0.10 < 0.001 0.005
SEC63 0.35 1.42 0.09 < 0.001 < 0.001
HSPH1 0.35 1.42 0.10 < 0.001 0.004
CCT8 0.40 1.49 0.10 < 0.001 0.001
CCT4 0.40 1.49 0.10 < 0.001 < 0.001
HSP90AA1 0.40 1.49 0.09 < 0.001 < 0.001
HSPA8 0.41 1.51 0.12 < 0.001 0.004
DNAJC13 0.46 1.58 0.11 < 0.001 < 0.001
HSPA9 0.46 1.58 0.10 < 0.001 < 0.001
TCP1 0.50 1.64 0.10 < 0.001 < 0.001
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prognosis in hepatocellular carcinoma [33], has been im-
plicated in osteosarcoma tumorigenesis [34], and appeared
as a candidate biomarker in epithelial ovarian cancer [35]
and in cholangiocarcinoma patients [36]. CCT3 was found
differentially expressed in colon and other epithelial can-
cers [37] and its expression has been associated with drug
resistance in a squamous lung cancer cell line [38]. CCT5
was found upregulated in p53-mutated breast tumours
and might be implicated in resistance to docetaxel treat-
ment [39]. Of notice, all the other TRiC genes except
CCT6B were also among the most highly expressed in
cancer and upregulated accordingly in the different sub-
types, suggesting an important role of the TRiC complex
specifically in BRCA as previously suggested [40]. TRiC
has an essential role in cell proteostasis in physiological
conditions but also in oncogenesis and cancer progression
[41] and is known to regulate the proper folding of several
others genes involved in cancer such as actin, tubulin [42],
p53 [43] and protoncogene STAT3 [44]. In our study,
HSP-Clust II (enriched with Basal-like tumours) presented
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Fig. 5 HSPs gene expression heatmap of TCGA BRCA cohorts. Expression patterns of 89 HSP genes in 1033 samples are depicted (central panel,
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high expression levels of the TRiC complex genes. The
current standard of treatment of triple-negative (TNBC) tu-
mours is systemic neoadjuvant chemotherapy that typically
include taxanes which inhibit tubulin depolymerization
[45]. We hypothesize that the measurement of the TRiC
complex genes along with the classification of tumour sam-
ples in the different HSP-Clusts could be used as an im-
portant tool to predict taxane response, even though
further studies are needed to validate this assumption.
Coming back to HSPE1, in a previous proteomic ana-
lysis this protein appeared with altered expression in
MDA-MB-231 breast cancer cells (triple negative highly
aggressive cells) [46] and both HSPD1/HSPE1 have also
been found upregulated in other cancer types associated
with tumour cell transformation [47]. Interestingly, both
TRiC genes and HSPD1/HSPE1 were co-expressed and
were associated with worst prognosis individually and
had high expression in the HSP-Clust II and III of our
study (Additional file 10 B). All this data together sug-
gest that not only the TRiC complex has a protagonist
role in cancer behaviour but also that the HSPD1/
HSPE1 complex is involved tightly with TRiC in proteos-
tasis regulation, an association that is poorly understood
in breast cancer and should be further studied. On the
other hand, BBS12 was underexpressed in the HER2
subtype predominantly and along with BBS10, both
showed decreased expression levels in all subtypes. MKKS
gene (also known as BBS6) was not altered. Therefore, our
study reveals specific chaperones that participate in the as-
sembly of the BBSome altered in BRCA.
The HSP70 family is a group of evolutionary con-
served and ubiquitously expressed genes that in con-
junction with the DNAJ family act as a protein folding
regulatory network that also protects the cell against
stressful conditions [48]. Several members of the HSP70
family were found highly expressed (HSPA8, HSPA5,
HSPA1A) or upregulated in BRCA. We found that
HSPA6 expression appeared elevated mainly in Luminal
A, Luminal B and Basal subtypes. In a previous study
high levels of this protein were associated with recur-
rence in hepatocellular carcinoma [49]. HYOU1 also
known as oxygen-regulated protein 150 (ORP150) was
upregulated in HER2 and Basal subtypes and the protein
has been implicated with tumour progression in differ-
ent cancers [50–53]. HSPA5 was found highly expressed
in all subtypes, and especially upregulated in Basal tu-
mours in our study, and has been associated with endo-
plasmic reticulum stress response (ERSR), inhibition of
apoptosis and autophagy in several studies [54–56].
HSPA8 was the most expressed gene of the HSP70 fam-
ily and one of the genes with the strongest association
with survival in our study. This gene is constitutively
expressed and has been largely associated with the
protein folding and stress response [57, 58]. Interest-
ingly, DNAJC12, a gene strongly upregulated in
Luminal A and B tumours, was found to interact with
HSPA8 under ERSR [59].
Only one HSP appeared upregulated in the four sub-
types considered: the protein encoded by DNAJC5B,
which is implicated in protein processing at the level of
the endoplasmic reticulum [60]. This protein has been
found in secretory vesicles as well as in synaptic and
clathrin-coated vesicles in neuroendocrine, exocrine and
nervous cells. Of interest is that this member of the
DNAJ family has been found upregulated in human
bladder carcinoma, gastric adenocarcinoma, and glio-
blastoma cell lines by the OCT4B1 variant (octamer-
binding transcription factor 4 B1 variant) which is
expressed by pluripotent normal and cancer stem cell
lines and linked to anti-apoptosis [61]. In addition, these
authors found that the OCT4B1 variant is also linked to
upregulation of the chaperonin DNAJC11 which is
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Fig. 6 HSP cluster characterization. a) Agreement between PAM50
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complexed with mitofilin in the mitochondrial mem-
brane [62] and has been associated with neuromuscular
diseases and lymphoid abnormalities [63]. In this study,
DNAJC11 appeared slightly upregulated in Luminal B,
HER2 and Basal subtypes. No attention has been
directed to these proteins (DNAJC5B and DNAJC11) in
BRCA. It is now evident that further studies must be di-
rected to clarify the role of these proteins. DNAJC9 ap-
peared upregulated in Basal, HER2 and Luminal B, and
in previous studies has been found upregulated in
node-positive uterine cervical carcinoma [64].
Our study revealed HSPs that appeared both deregu-
lated and not well studied in BRCA; for example,
DNAJB3 appeared with high levels of upregulation only
in HER2 BRCA subtype. Close gene location with HER2
gene cannot explain upregulation of DNAJB3 since this
gene is located on chromosome 2 while HER2 (amplified
in HER2 subtype) is located on chromosome 17. Little is
known about the protein encoded by this gene, and its
role in cancer in general and in breast cancer in particu-
lar is not known. DNAJB3 has been reported downregu-
lated in obese human subjects, DNAJB3 over-expression
in adipose cell lines caused: a) reduction in JNK (Jun
N-terminal kinase) improving insulin sensitivity and en-
hancing glucose uptake and b) mediated PI3K/AKT
pathway activation [65]. Of interest here is that the
PI3K/Akt signalling pathway is negatively regulated by
PTEN and we have reported that PTEN is downregulated
by HSPB1 (HSP27), both proteins have been implicated in
HER2-positive tumours [66]. Therefore, it will be of inter-
est to study the role of DNAJB3 in HER2 BRCA. However,
we have to take into account that the upregulation levels
of this gene might appear statistically significant, but the
number of RNA molecules could be relatively low. There-
fore, an upregulated gene could have few RNA copy num-
bers and we ignore if the encoded protein has biological
significance. Nevertheless, this entire complex HSP70/
DNAJ landscape suggests an intricate regulatory inter-
action between these genes that remains to be untangled.
Finally, among the upregulated small heat shock pro-
teins, HSPB1 stands out as the highest expressed of the
group and appeared upregulated in Luminal A, Luminal
B, and HER2 (close to the cut-point in Basal); the pro-
tein encoded by this gene has been well studied in breast
cancer [4, 67].
Many of these upregulated genes and proteins
have been reported as associated with tumour pro-
gression in different cancer types and in several op-
portunities with poor prognosis. In concordance, we
have found that some of these genes appeared up-
regulated mainly in aggressive breast cancer sub-
types that were clustered in the HSP-Clust III
group. Moreover, the complexity of the regulation of
the HSPs in BRCA is further increased when we consider
the high number of client proteins that are associated
with the HSPs [11].
Variables
HSP-Clust II vs HSP-Clust I
HSP-Clust III vs HSP-Clust I
Age
Positive node status
Tumor size  >2 cm
Tumor stage II
Tumor stage III
Tumor stage IV
LumB vs LumA
Her2 vs LumA
Basal-like vs LumA
No of Patients (%)
190 (18.94%)
361 (35.99%)
58.28(mean)
483 (48.16%)
744 (74.18%)
582 (58.03%)
232 (23.13%)
17 (1.69%)
203 (20.24%)
75 (7.48%)
188 (18.74%)
Hazard Ratio (95% CI)
2.508 (0.68−9.24)
1.608 (0.9−2.88)
1.042 (1.02−1.06)
0.577 (0.3−1.13)
0.974 (0.45−2.1)
1.285 (0.41−4.02)
2.228 (0.57−8.71)
3.827 (0.81−18.02)
1.338 (0.71−2.53)
3.227 (1.53−6.8)
1.239 (0.33−4.61)
p−value
0.167
0.111
5.22e−06
0.108
0.946
0.667
0.249
0.0896
0.369
0.00207
0.749
1 2 3 4 5
Hazard Ratio
b
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58.28(mean)
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744 (74.18%)
582 (58.03%)
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17 (1.69%)
Hazard Ratio (95% CI)
2.829 (1.55−5.17)
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0.601 (0.31−1.17)
0.92 (0.43−1.98)
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p−value
0.000727
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a
Fig. 7 Multivariable Cox Model of HSP-Clusts. a) Forest plot showing the hazard risk of HSP-Clusters controlling for confounders (age, node status,
tumour size, tumour stage). Hazard ratios, 95% confidence interval and corresponding P values are depicted. b) Same Cox’s model plus de addition of
PAM50 subtypes as covariates
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Another interesting observation from the present
study is that several HSPs were downregulated in all
breast cancer subtypes: DNAJB4, DNAJC18, HSPA12A,
HSPA12B, HSPB2, HSPB6, and HSPB7. DNAJB4 is a
member of the DNAJ family and is described as a
tumour suppressor [68], which is in agreement with our
results; increased expression of DNAJB4 has been impli-
cated in the stabilization of wild-type E-cadherin (but
not the mutant) stimulating the anti-invasive function of
E-cadherin in gastric cancer cells [68]. Little is known
about the protein coded by DNAJC18, but a poly-
morphic variant has been associated with aggressive
bladder carcinoma [69]. HSPA12A encodes a protein of
the HSP70 family that seems to act like a protective
factor in gastric cancer [70]. We found high levels of
suppression in several members of the HSPB family
(CRYAB, HSPB2, HSPB6 and HSPB7) (Fig. 3); in an inte-
grated genomic and epigenomic analysis the ATM,
HSPB2 and CRYAB (this last downregulated in Luminal
A, Luminal B and Basal) genes were found commonly
deleted and underexpressed in patients with breast can-
cer brain metastasis [71]. The role of CRYAB gene
(Alpha B-crystallin HSPB5) is controversial in cancer
[72–79], its expression has been associated with aggres-
sive breast cancer subtypes. In agreement with our
results, HSPB6 and HSPB7 have been found downregu-
lated in several tumour types [80–85], and we report
here this downregulation in all subtypes of BRCA is pos-
sibly supporting a role as tumour suppressor genes. In
our analyses we compared tumour tissue with normal
breast tissue, but displacement of stroma in the tumour
samples could be affecting the results. Nevertheless, in a
recent publication none of the HSP genes were found al-
tered by the confounding effect of tumour purity [86].
The HSPs expression patterns of the molecular subtypes
are still heterogeneous [15] and the results of the present
study contribute to the characterization of these sub-
types. We are now completing the study of the methyla-
tion status of the HSP genes as well as the mutations,
amplifications and deletions in these genes.
Of importance, we have to mention that some genes
evaluated in this work presented clinically and biologic-
ally meaningful characteristics already described, but
some others genes are totally unknown at the moment
[87]. The clinically important genes DNAJB5, HSCB,
HSPA2 (usually differentially overexpressed in Luminal
A and B), DNAJC4, and HSPA12B (downregulated in
BRCA) presented a significant FDR value in the Cox’s
proportional hazard model presenting negative coeffi-
cients (their expression was associated with a good prog-
nosis). In contrast, the genes with high expression levels
significantly associated with poor prognosis were:
CCT6A, HSPA14, DNAJC6 (upregulated in Basal),
CCT2 (upregulated in Luminal B), CCT5, HSPD1
(upregulated in Basal, Luminal B and HER2), SEC63
(upregulated in HER2), TCP1, CCT4, CCT7, CCT8
(upregulated in HER2 and Basal), HSP90AA1 (upreg-
ulated with a near 0.9 log2 fold-change in Luminal B,
HER2 and Basal), HSPH1 (upregulated in Luminal B,
HER2), DNAJA2, HSPA9, HSPA4, DNAJC13, and
HSPA8. Many of which were previously mentioned
(HSP90AA1, TRiC, HSPD1/HSPE1, HSP70 family)
and others for which their role in BRCA has not been
exhaustively studied.
An important point of this study is the finding of three
discrete HSPs expression profiles with prognostic signifi-
cance (P = 0.0022) that we called HSP-Clust I, II and III.
These HSP clusters groups were reproduced in an inde-
pendent dataset using the METABRIC cohort and a sin-
gle sample predictor was trained to classify unknown
samples into one of the three HSP-Clusts with robust re-
sults. Importantly, TCGA and METABRIC datasets were
developed using different RNA measurement technolo-
gies but the clusters found showed striking similarities
and had significant impact on disease outcome. An
interesting point to address is that the HSP-Clust II
(predominantly basal-like) in METABRIC is much more
clearly associated with a poor prognosis than the same
signatures in the TCGA, a plausible explanation might
be found in the survival differences of Basal-like
tumours in each cohort (Additional file 12). Even though
HSP-Clusts survival is highly related to PAM50 subtypes
as expected, it is important to notice that the overlap be-
tween groups is not complete. Regarding Luminal
tumours, HSP-Clust I presented mainly Luminal A tu-
mours while HSP-Clust III presented mixed proportions
of Luminal A and Luminal B subtypes. These findings
could be reflecting differences in the biology of Luminal
A tumours from HSP-Clust I with respect to Luminal A
tumours of HSP-Clust III. Also, since HSPs have been
long related with drug resistance, it would be of interest
to test if the different HSP-Clust are related with differ-
ent chemotherapy response profiles, which in turn,
could imply a differential treatment for each HSP-Clust
group. Further studies will be necessary to turn this clas-
sification useful for clinical practice and to better
characterize the prognostic and treatment for these
groups of patients. Since we used a combination of all
HSP genes to evaluate survival, this could add superflu-
ous information that can reduce the performance of the
study. It will be interesting to reduce the number of
HSP genes in order to increase the potential of the HSPs
expression patterns as a prognostic factor. For in-
stance, the clinical subset of HSP genes with clinical
importance could be used as a genetic signature to
develop prognostic tests or as a base for future re-
search of predictive assays based on immunohisto-
chemistry, microarray or rPCR.
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Conclusions
Our results show the existence of several HSP genes
deregulated in all molecular subtypes of breast cancer
while others appeared deregulated in specific molecular
subtypes. We also found that the overall survival of
breast cancer patients appeared associated with the ex-
pression level of certain HSPs.
Additional files
Additional file 1: Table S1. Clinical data of TCGA patients. The data
was updated with the available follow up information (May, 2015).
Table S2. Gene mean expression in breast cancer tissues. The mean
expression of each gene in all cancer samples was calculated and
sorted in decreasing order. Table S3. Summary of misregulated genes in
BRCA. Tabulated data show the number and percentages of total genes
and HSP genes presenting > 2 fold-change in total samples and according
to intrinsic BRCA subtypes. Table S4. Summary of PAM50 classification and
immunohistochemical characteristics of tumours. (XLSX 1080 kb)
Additional file 2: Data analysis workflow. Schematic representation of
HSPs transcriptomic and survival analysis process. (PDF 108 kb)
Additional file 3: PAM50 classification quality control of TCGA’s samples
I. A) Principal components analysis of the training and test sets. Note the
subtype clustering and the superposition between both datasets. B)
Correlations between subtype assigned and the corresponding subtype
centroids per sample and relation between subtypes and proliferation
index. Each dot represents a single sample. (PDF 166 kb)
Additional file 4: PAM50 classification quality control of TCGA’s samples
II. Unsupervised hierarchical clustering of samples according to PAM50
gene set expression. Note the consistency between the subtype assigned
to each sample by PAM50 algorithm and the group composition determined
by the clustering technique. (PDF 133 kb)
Additional file 5: Differential gene expression of 20,531 genes comparing
cancer tissue against normal breast tissue. The values were determined by
EdgeR and DESeq2 methods; also the analysis was performed according
molecular subtype classification. For better data exploration HSP genes were
separated in auxiliary tables. (XLSX 22435 kb)
Additional file 6: Fold-change consistency between EdgeR and DESeq2
methods. A) Correlation analysis between fold-change obtained by both
methods. The figure shows a tight linear trend between EdgeR and DESeq2
fold-change estimations. Genes found significant for both methods are
represented in yellow circles, in green and red are genes significantly
differentially expressed by one of the two methods and in white, genes with
no significant changes by both techniques. B) Bland Altman analysis comparing
the mean fold-changes of both methods (x-axis) and the difference between
them (y-axis). This plot allows the identification of any systematic difference
between methods and possible outliers. Each circle represents an HSP gene
and their colours the subtype for which the fold-change was calculated. The
blue dotted line represents the mean difference between both techniques
(0.02) and the light blue dashed line depicts the upper (0.88) and lower (− 0.84)
limits of the 95% confidence interval of the differences. (PDF 175 kb)
Additional file 7: HSPs differential gene expression between tumour tissues.
The values were determined by EdgeR ANOVA-like method performed on
20,531 genes from BRCA TCGA. Only HSPs values are showed. Each column
includes log2 fold change values for all comparison, log2 mean counts per
million (logCPM), F-statistic and corresponding p-values and FDR values. The
conditions compared are Luminal A vs. Luminal B, Luminal A vs. HER2,
Luminal A vs. Basal-like, Luminal B vs. HER2, Luminal B vs. Basal-like
and HER2 vs. Basal-like. Comparison between HSP-Clusts were also
considered, namely HSP-Clust I vs. HSP-Clust II, HSP-Clust I vs HSP-Clust III
and HSP-Clust II vs. HSP-Clust III. (XLSX 35 kb)
Additional file 8: Dendrogram analysis of hierarchical clustering based
on HSPs gene expression. The separation distance between branches was
determined by silhouette technique. The highest coefficient corresponds
to the optimal number of cluster, in this case k = 3. (PDF 99 kb)
Additional file 9: Summary of HSP subfamily Fold Change trends across
PAM50 subtypes. Boxplot representing HSP subfamilies log2 fold change
ranges by EdgeR method in the different molecular subtypes of breast
cancer. (PDF 111 kb)
Additional file 10: Differential gene expression in BRCA TCGA tumours.
Summary of EdgeR ANOVA-like differential gene expression showing the
HSPs pairwise differences between tumour subtypes. Genes were grouped
according to their corresponding families. Chaperonins were divided into
three different types (type I, type II and BBs chaperonins), HSPH were
distinguished from the rest of the HSP70 family and DNAJ were divided
into their three subfamilies (A, B and C). The vertical blue lines represents
baseline level from the reference subtype while the light blue points shows
the fold change of the HSP genes in each pairwise comparison. Red dots
are depicted for genes that had absolute log2 fold changes greater than 2.
A) Shows the comparison between PAM50 molecular subtypes, and B)
shows differences between HSP-Clust subtypes. (PDF 202 kb)
Additional file 11: HSP clusters characterization. A) Centroid of HSP
clusters expression profiles for TCGA, METABRIC training and test set. The
colour of the boxes in regard to the central dashed line represents down
(blue) or upregulation (red) of the gene in the corresponding cluster. The
continuous black line represents the mean expression values of each
gene in the cluster compared to the mean of the same gene over all
samples. B) Agreement between PAM50 and HSP clusters for METABRIC
training and test sets. The size of the bars is in proportion to the number
of samples in each category. C) Overall survival of HSP clusters for METABRIC
training and test sets. Kaplan-Meier curves corresponding to HSP-Clust I,
HSP-Clust II and HSP-Clust III. Statistical significance was evaluated by
Log-Rank test. (PDF 214 kb)
Additional file 12: PAM50 subtypes overall survival in TCGA and
METABRIC cohorts. (PDF 166 kb)
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